Virax Biolabs (VRAX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.45, -10.49% vs the prior close of $1.62.
- Volume 40.69K shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VRAX slides 10.5% to $1.45, a 52-week low, 7 down days in a row. Closed at $1.45, -10.49% vs the prior close of $1.62. Day range $1.38–$1.64, opened at $1.62.
VRAX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VRAX slides 10.5% to $1.45, a 52-week low, 7 down days in a row
- Closed at $1.45, -10.49% vs the prior close of $1.62. Day range $1.38–$1.64, opened at $1.62.
- Volume was 40.69K shares, 0.1x its 50-day average of 480.58K — lighter than usual.
- Price is -42.4% vs its 50-day average ($2.52) and -66.3% vs its 200-day average ($4.30).
- 52-week range $1.38–$21.75; today's close sits at 0% of that range, 93.3% below the 52-week high.
- That makes 7 straight losses.
Oct 15, 2026 — VRAX dips 1.8% to $1.62, a 52-week low, 6 down days in a row
- Closed at $1.62, -1.82% vs the prior close of $1.65. Day range $1.55–$1.76, opened at $1.66.
- Volume was 44.20K shares, 0.1x its 50-day average of 480.67K — lighter than usual.
- Price is -36.3% vs its 50-day average ($2.54) and -62.7% vs its 200-day average ($4.34).
- 52-week range $1.55–$21.75; today's close sits at 0% of that range, 92.6% below the 52-week high.
- That makes 6 straight losses.
Oct 14, 2026 — VRAX slides 5.1% to $1.65, a 52-week low, 5 down days in a row
- Closed at $1.65, -5.06% vs the prior close of $1.74. Day range $1.61–$1.78, opened at $1.77.
- Volume was 38.70K shares, 0.1x its 50-day average of 482.72K — lighter than usual.
- Price is -35.8% vs its 50-day average ($2.57) and -62.3% vs its 200-day average ($4.37).
- 52-week range $1.61–$21.75; today's close sits at 0% of that range, 92.4% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — VRAX slides 6.1% to $1.74, a 52-week low, 4 down days in a row
- Closed at $1.74, -6.05% vs the prior close of $1.85. Day range $1.72–$1.86, opened at $1.80.
- Volume was 39.70K shares, 0.1x its 50-day average of 492.48K — lighter than usual.
- Price is -33.1% vs its 50-day average ($2.60) and -60.6% vs its 200-day average ($4.41).
- 52-week range $1.72–$21.75; today's close sits at 0% of that range, 92.0% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — VRAX dips 1.1% to $1.85, a 52-week low, 3 down days in a row
- Closed at $1.85, -1.07% vs the prior close of $1.87. Day range $1.78–$1.90, opened at $1.81.
- Volume was 71.00K shares, 0.1x its 50-day average of 492.36K — lighter than usual.
- Price is -29.4% vs its 50-day average ($2.62) and -58.4% vs its 200-day average ($4.45).
- 52-week range $1.78–$21.75; today's close sits at 0% of that range, 91.5% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — VRAX slides 6.0% to $1.87, a 52-week low
- Closed at $1.87, -6.03% vs the prior close of $1.99. Day range $1.81–$1.94, opened at $1.92.
- Volume was 87.60K shares, 0.2x its 50-day average of 491.46K — lighter than usual.
- Price is -29.1% vs its 50-day average ($2.64) and -58.3% vs its 200-day average ($4.48).
- 52-week range $1.81–$21.75; today's close sits at 0% of that range, 91.4% below the 52-week high.
- SEC filings that day: 6-K.
Oct 8, 2026 — VRAX slides 5.7% to $1.99, a 52-week low
- Closed at $1.99, -5.69% vs the prior close of $2.11. Day range $1.93–$2.13, opened at $2.13.
- Volume was 50.80K shares, 0.1x its 50-day average of 491.12K — lighter than usual.
- Price is -25.0% vs its 50-day average ($2.65) and -56.0% vs its 200-day average ($4.52).
- 52-week range $1.83–$21.75; today's close sits at 1% of that range, 90.9% below the 52-week high.
Oct 7, 2026 — VRAX jumps 3.9% to $2.11
- Closed at $2.11, +3.94% vs the prior close of $2.03. Day range $1.83–$2.18, opened at $2.02.
- Volume was 271.50K shares, 0.6x its 50-day average of 487.14K — lighter than usual.
- Price is -21.1% vs its 50-day average ($2.67) and -53.7% vs its 200-day average ($4.56).
- 52-week range $1.83–$21.75; today's close sits at 1% of that range, 90.3% below the 52-week high.
Oct 6, 2026 — VRAX slides 15.4% to $2.03, a 52-week low
- Closed at $2.03, -15.42% vs the prior close of $2.40. Day range $1.83–$2.33, opened at $2.33.
- Volume was 310.50K shares, 0.6x its 50-day average of 481.98K.
- Price is -24.5% vs its 50-day average ($2.69) and -55.8% vs its 200-day average ($4.60).
- 52-week range $1.83–$21.75; today's close sits at 1% of that range, 90.7% below the 52-week high.
Oct 5, 2026 — VRAX jumps 9.1% to $2.40 on 6.8x normal volume
- Closed at $2.40, +9.09% vs the prior close of $2.20. Day range $2.16–$3.34, opened at $2.53.
- Volume was 2.90M shares, 6.8x its 50-day average of 425.81K — unusually heavy trading.
- Price is -11.4% vs its 50-day average ($2.71) and -48.3% vs its 200-day average ($4.64).
- 52-week range $2.04–$21.75; today's close sits at 2% of that range, 89.0% below the 52-week high.
Oct 2, 2026 — VRAX dips 1.8% to $2.20
- Closed at $2.20, -1.79% vs the prior close of $2.24. Day range $2.13–$2.25, opened at $2.21.
- Volume was 19.60K shares, 0.0x its 50-day average of 429.09K — lighter than usual.
- Price is -19.3% vs its 50-day average ($2.73) and -52.9% vs its 200-day average ($4.68).
- 52-week range $2.04–$21.75; today's close sits at 1% of that range, 89.9% below the 52-week high.
VRAX latest news & SEC filings
Every SEC filing by or about VRAX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 10, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 4, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 4, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 26, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 24, 2026 · Form F-3 — F-3 filing
F-3 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 16, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 10, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 6, 2026 · Form 20-F — Annual report from a foreign company (20-F)
Annual report from a foreign company (20-F)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Jun 24, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade VRAX
- How much it moves: over the last 20 sessions the average daily move was 5.18% (largest 15.4%). That is a volatile stock.
- Liquidity: about 209.46K shares (≈$303.72K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.45 vs a range of $1.38–$21.75 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:25 on Jun 26, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Oct 9, 2026; 6-K Sep 4, 2026; 6-K Aug 26, 2026.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
VRAX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.62 | 1.64 | 1.38 | 1.45 | 40.69K |
| Oct 15, 2026 | 1.66 | 1.76 | 1.55 | 1.62 | 44.20K |
| Oct 14, 2026 | 1.77 | 1.78 | 1.61 | 1.65 | 38.70K |
| Oct 13, 2026 | 1.80 | 1.86 | 1.72 | 1.74 | 39.70K |
| Oct 12, 2026 | 1.81 | 1.90 | 1.78 | 1.85 | 71.00K |
| Oct 9, 2026 | 1.92 | 1.94 | 1.81 | 1.87 | 87.60K |
| Oct 8, 2026 | 2.13 | 2.13 | 1.93 | 1.99 | 50.80K |
| Oct 7, 2026 | 2.02 | 2.18 | 1.83 | 2.11 | 271.50K |
| Oct 6, 2026 | 2.33 | 2.33 | 1.83 | 2.03 | 310.50K |
| Oct 5, 2026 | 2.53 | 3.34 | 2.16 | 2.40 | 2.90M |
| Oct 2, 2026 | 2.21 | 2.25 | 2.13 | 2.20 | 19.60K |
| Oct 1, 2026 | 2.18 | 2.37 | 2.18 | 2.24 | 30.80K |
| Sep 30, 2026 | 2.25 | 2.27 | 2.13 | 2.18 | 19.50K |
| Sep 29, 2026 | 2.27 | 2.39 | 2.04 | 2.23 | 94.00K |
| Sep 28, 2026 | 2.35 | 2.35 | 2.30 | 2.31 | 5.50K |
| Sep 25, 2026 | 2.38 | 2.60 | 2.38 | 2.39 | 13.40K |
| Sep 24, 2026 | 2.28 | 2.47 | 2.28 | 2.44 | 20.60K |
| Sep 23, 2026 | 2.52 | 2.60 | 2.50 | 2.55 | 14.30K |
| Sep 22, 2026 | 2.38 | 2.65 | 2.29 | 2.50 | 51.00K |
| Sep 21, 2026 | 2.48 | 2.54 | 2.14 | 2.31 | 70.80K |
About Virax Biolabs
Virax Biolabs (VRAX) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in LANARKSHIRE, United Kingdom. State of incorporation: Cayman Islands. Fiscal year ends March 31. SEC CIK 1885827.
VRAX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Nelson M Haight | Director | Mar 31, 2026 |
| Nigel William Mccracken | Chief Operating Officer | Mar 20, 2026 |
| Iain David Miller | Director | Mar 18, 2026 |
| Evan Michael Norton | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jason Davis | Chief Financial Officer | Mar 18, 2026 |
| James Alexander Cunliffe Foster | Chief Executive Officer | Mar 18, 2026 |
| Nigel William Mccracken | Chief Operating Officer | Mar 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
VRAX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
VRAX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Celldex Therapeutics (CLDX)Intellia Therapeutics (NTLA)Neogen (NEOG)QuidelOrtho (QDEL)Achieve Life Sciences (ACHV)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Q/C Technologies (QCLS)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VRAX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.